Amer Zeidan MBBS, MHSAssistant Professor of Medicine (Hematology), Yale University, New Haven, CT
Amer Zeidan, MBBS, MHS is an Assistant Professor of Medicine (Hematology) at Yale University. Dr. Zeidan completed a hematology/oncology fellowship and a clinical research fellowship in myelodysplastic syndromes (MDS) at Johns Hopkins University where he also earned a Master of Health Science (MHS) degree in Clinical Investigation. He received his MBBS degree from the Faculty of Medicine, University of Jordan, Amman, Jordan before completing his internal medicine residency at Rochester General Hospital, Rochester, NY.
Dr. Zeidan specializes in the management of blood cancers especially MDS and acute myeloid leukemia (AML). He is a nationally recognized expert in the clinical management of these diseases and is a member of the National Comprehensive Cancer Network (NCCN) clinical guideline panel for MDS. The focus of Dr. Zeidan’s clinical/translational research is the development of novel therapies for MDS, AML, and other hematologic malignancies. Dr. Zeidan is the principal investigator on several clinical trials in MDS, AML and other hematologic malignancies. Dr. Zeidan especially focuses on the use of immunotherapies (drugs that stimulate the patient's own immune system) including the immune checkpoint inhibitors to fight blood cancers.
The second area of research interest for Dr. Zeidan is effectiveness and outcomes research in hematologic malignancies; a type of research that evaluates how much benefit do patients achieve from existing treatments at the real-world community level in comparison to what is seen in the controlled clinical trials setting. Dr. Zeidan conducts this research within the Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center at Yale University.
Dr. Zeidan has been awarded the American Society of Clinical Oncology Young Investigator Award (ASCO YIA), the Aplastic Anemia and MDS International Foundation (AAMDSIF)/Ed Evan’s Foundation- MDS Clinical Research Consortium Fellowship award, The TITO BASTIANELLO Young Investigator Award and multiple abstract achievement and travel awards. Dr. Zeidan has presented his research in multiple national and international meetings and is an author on more than 110 peer-reviewed publications and book chapters.
Acknowledgement/funding: Amer Zeidan is a Leukemia and Lymphoma Society Scholar in Clinical Research and is also supported by a NCI’s Cancer Clinical Investigator Team Leadership Award (CCITLA). Research reported in this publication was in part supported by the National Cancer Institute of the National Institutes of Health under Award Number P30 CA016359. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Declaration of conflicts of interest: A.M.Z. received research funding (institutional) from Celgene, Acceleron, Abbvie, Otsuka, Pfizer, Medimmune/AstraZeneca, Boehringer-Ingelheim, Trovagene, Incyte, Takeda, Novartis, and ADC Therapeutics. A.M.Z had a consultancy with and received honoraria from AbbVie, Otsuka, Pfizer, Celgene, Jazz, Ariad, Incyte, Agios, Boehringer-Ingelheim, Novartis, Acceleron, Astellas, Daiichi Sankyo, Cardinal Health, Seattle Genetics, BeyondSpring, Trovagene, Ionis, Epizyme, and Takeda. A.M.Z received travel support for meetings from Pfizer, Novartis, and Trovagene. None of these relationships were related to the development of this manuscript.